Illumina Stock Today
| ILMN Stock | USD 126.25 1.42 1.14% |
Performance9 of 100
| Odds Of DistressLess than 16
|
Illumina is selling at 126.25 as of the 13th of September 2024; that is 1.14 percent increase since the beginning of the trading day. The stock's open price was 124.83. Illumina has less than a 16 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Note, on May 30, 2024, Representative Thomas H Kean of US Congress acquired under $15k worth of Illumina's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of July 2000 | Category Healthcare | Classification Health Care |
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. The company was incorporated in 1998 and is based in San Diego, California. Illumina operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 159.3 M outstanding shares of which 4.47 M shares are currently shorted by private and institutional investors with about 2.26 trading days to cover. More on Illumina
Moving together with Illumina Stock
| 0.84 | A | Agilent Technologies Fiscal Year End 18th of November 2024 | PairCorr |
| 0.81 | DSGN | Design Therapeutics Trending | PairCorr |
| 0.69 | VRAX | Virax Biolabs Group | PairCorr |
| 0.65 | VRDN | Viridian Therapeutics Trending | PairCorr |
| 0.62 | ERAS | Erasca Inc | PairCorr |
Moving against Illumina Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Illumina Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Jacob Thaysen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Measuring and Control Equipment (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Nasdaq CTA Artificial, NASDAQ Biotechnology, ARCA Biotechnology, Dow Jones Biotechnology, NASDAQ 100 Pre, SP Midcap 400, NASDAQ Composite Total, Measuring and Control Equipment, Health Care, Life Sciences Tools & Services, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal TestingCatholic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsIllumina can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Illumina's financial leverage. It provides some insight into what part of Illumina's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Illumina (ILMN) is traded on NASDAQ Exchange in USA. It is located in 5200 Illumina Way, San Diego, CA, United States, 92122 and employs 10,590 people. Illumina is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 20.11 B. Illumina conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 159.3 M outstanding shares of which 4.47 M shares are currently shorted by private and institutional investors with about 2.26 trading days to cover.
Illumina currently holds about 2.01 B in cash with 477 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.62.
Check Illumina Probability Of Bankruptcy
Ownership AllocationIllumina has a total of 159.3 Million outstanding shares. The majority of Illumina outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Illumina to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Illumina. Please pay attention to any change in the institutional holdings of Illumina as this could imply that something significant has changed or is about to change at the company. Please note that on May 30, 2024, Representative Thomas H Kean of US Congress acquired under $15k worth of Illumina's common stock.
Check Illumina Ownership Details
Illumina Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Primecap Management Company | 2024-06-30 | 2.4 M | |
| Corvex Management Lp | 2024-06-30 | 2.3 M | |
| Norges Bank | 2024-06-30 | 2.1 M | |
| Nuveen Asset Management, Llc | 2024-06-30 | 1.9 M | |
| Guardcap Asset Management Limited | 2024-06-30 | 1.8 M | |
| Bank Of America Corp | 2024-06-30 | 1.6 M | |
| Legal & General Group Plc | 2024-06-30 | 1.6 M | |
| Hhg Plc | 2024-06-30 | 1.5 M | |
| Amundi | 2024-03-31 | 1.5 M | |
| Blackrock Inc | 2024-06-30 | 18.1 M | |
| Vanguard Group Inc | 2024-06-30 | 15.9 M |
Illumina Historical Income Statement
Illumina Stock Against Markets
Illumina Corporate Management
| Scott Ericksen | VP Officer | Profile | |
| Kevin Pegels | Chief Operations | Profile | |
| Charles Esq | Senior Counsel | Profile | |
| Joydeep MBA | Executive Officer | Profile | |
| Sharon Vidal | Global Responsibility | Profile | |
| Jakob Wedel | Chief Staff | Profile | |
| Steven Hoffman | Segment Sequencing | Profile |
Additional Information and Resources on Investing in Illumina Stock
When determining whether Illumina offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Illumina's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Illumina Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Illumina Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Illumina. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Illumina Stock, please use our How to Invest in Illumina guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Illumina. If investors know Illumina will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Illumina listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share (19.16) | Revenue Per Share 27.943 | Quarterly Revenue Growth (0.05) | Return On Assets 0.0144 |
The market value of Illumina is measured differently than its book value, which is the value of Illumina that is recorded on the company's balance sheet. Investors also form their own opinion of Illumina's value that differs from its market value or its book value, called intrinsic value, which is Illumina's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Illumina's market value can be influenced by many factors that don't directly affect Illumina's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Illumina's value and its price as these two are different measures arrived at by different means. Investors typically determine if Illumina is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Illumina's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.